Recent reports in the JAMA Internal Medicine indicate that patients taking Januvia are at a higher risk of developing pancreatitis when compared with those taking other Type 2 diabetic drugs which do not contain sitaglipin. The JAMA journal found that those suffering from pancreatitis who were hospitalized were twice as likely to have been taking Januvia.  Januvia is an oral anti-hyperglycemic belonging to a class of drugs known as incretin mimetics which stimulate the production of insulin. 

As more time passes, it appears more people are coming forward to say they have been harmed by a drug they believed to be safe—in this case, Januvia.  Januvia, manufactured by Merck & Co., is a drug used in the treatment of Type 2 diabetes. Januvia controls blood sugar when the body is unable to do so and is meant to be used in conjunction with diet and exercise. Sitagliptin, the active ingredient in Januvia, works by inhibiting an enzyme known as DPP-4 which breaks down the hormones sending signals to the pancreas to produce more insulin. After FDA approval in 2006, scores of adverse reports were submitted to the FDA by Januvia users and recent studies show a definite link between Januvia and pancreatitis, pancreatic cancer and thyroid cancer.